BMRNHealthcare · BiotechnologyThe 25 Wall Street analysts covering BioMarin Pharmaceutical, Inc. hold a median 12-month price target of $86 — +27.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 15 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores BioMarin Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BMRN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +27.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $111 → $114 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | $50 → $60 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | $119 → $124 |
| 7 Aug 2026 | Oppenheimer | Maintains | Outperform | $95 → $97 |
| 16 July 2026 | Citigroup | Maintains | Buy | — |
| 16 July 2026 | Citigroup | Maintains | Buy | $75 → $76 |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | $66 → $62 |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 22 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 May 2026 | B of A Securities | Maintains | Buy | — |
| 19 May 2026 | Citigroup | Initiates | Buy | — |
| 18 May 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 11 May 2026 | Goldman Sachs | Reinstates | Neutral | $69 |
| 7 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 May 2026 | Bernstein | Maintains | Outperform | — |
| 5 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 5 May 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 5 May 2026 | RBC Capital | Reiterates | Sector Perform | — |
| 11 Mar 2026 | B of A Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMRN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 4% of US stocks
Cheaper than 34% of US stocks
Cheaper than 46% of US stocks
Cheaper than 11% of US stocks
Higher than 70% of US stocks
Higher than 4% of US stocks
Higher than 90% of US stocks
Higher than 80% of US stocks
Higher than 52% of US stocks
Higher than 46% of US stocks
Higher than 67% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioMarin Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reported on how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Why it matters — This item offers BMRN watchers a comparison of the company's year-to-date performance against its sector and a peer.
A Zacks Investment Research article lists BioMarin among five undervalued stocks worth buying in August, highlighting its low price-to-book ratio alongside Invesco, Centene, HPE and Gibraltar Industries.
Why it matters — The article identifies BioMarin as an undervalued stock based on its low price-to-book ratio, which BMRN watchers may see as notable market positioning.
Zacks Investment Research compares BioMarin Pharmaceutical (BMRN) and Illumina (ILMN) as potential options for investors seeking undervalued stocks in the Medical - Biomedical and Genetics sector, asking which of the two is the better value option.
Why it matters — BioMarin watchers would care because the piece directly evaluates BMRN's value relative to a sector peer, Illumina, which could inform how the stock is viewed in the investment community.
Zacks Investment Research reported that the mean of analysts' price targets for BioMarin points to a 28.2% upside in the stock, while noting this metric has not proven highly effective. It also noted that strong agreement among analysts in raising earnings estimates indicates an upside in the stock.
Why it matters — A BMRN watcher would care because the article highlights analyst expectations of upside and their consensus on rising earnings estimates for the company.
Zacks Investment Research highlights BioMarin Pharmaceutical as a top value stock for the long term, citing its Style Scores system that helps investors identify top-rated stocks by investing style.
Why it matters — A BMRN watcher would care because the item positions the company as a strong long-term value pick according to Zacks' quantitative stock-ranking system.
The 25 Wall Street analysts covering BioMarin Pharmaceutical, Inc. have a median 12-month price target of $86, with estimates ranging from $60 to $124. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 25 analysts covering BioMarin Pharmaceutical, Inc., 19 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioMarin Pharmaceutical, Inc. 59 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, BioMarin Pharmaceutical, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 25 analysts implies +27.7% from the last close, and Ticker Nerd's factor model ranks BioMarin Pharmaceutical, Inc. 59 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioMarin Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $124 over the next 12 months.
BioMarin Pharmaceutical, Inc. returned +16.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Biomarin Pharmaceutical Inc. is a global biotechnology company specializing in therapies for rare, genetically defined diseases.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?". Zacks Investment Research reported on how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Biomarin Pharmaceutical Inc. is a global biotechnology company specializing in therapies for rare, genetically defined diseases. The company focuses on developing and commercializing targeted treatments that address the underlying biology of serious inherited conditions, particularly enzyme deficiencies, skeletal disorders, and other complex genetic disorders. Its portfolio today includes enzyme replacement therapies, small-molecule and peptide drugs, and gene therapy for indications such as mucopolysaccharidoses, phenylketonuria, achondroplasia, severe hemophilia A, and certain neurodegenerative pediatric diseases. Biomarin Pharmaceutical Inc. generates most of its business from product sales to hospitals, specialty pharmacies, government agencies, and distributors, serving patients across North America, Europe, Latin America, the Middle East, and Asia-Pacific. Founded in 1997 and headquartered in San Rafael, California, the company plays a significant role in the rare disease segment of the biotechnology and pharmaceutical industries, providing highly specialized treatments where medical need is substantial and alternative options are limited.
CEO Mr. Alexander Hardy · 3,221 employees · United States · https://www.biomarin.com